Maze Therapeutics, Inc.
Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.
Vertex Pharmaceuticals (VRTX) and Maze Therapeutics (MAZE) saw stock increases after positive results from Vertex's kidney disease drug trial. Both companies are developing treatments for APOL1-mediated kidney disease (AMKD). Vertex tested its experimental treatment on patients with moderate proteinuria.
Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MAZE (Maze Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent MAZE coverage spans insider activity, market movers and financial news.
In the last 30 days, MAZE insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($2.9M). The most active reporter was Bernstein Harold, President, R&D & CMO, with 6 filings. 24% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst initiation and price target lift the stock, supporting further upside.
Rival's stock benefits from sector momentum.
Analyst upgrade and high price target suggest strong upside on comparable efficacy expectations.
The insider liquidation may signal reduced confidence and could pressure the stock lower.
The sale signals potential downside pressure as insiders are reducing stakes without offsetting buys.
AlphAI scores every news story that mentions MAZE with an AI model for sentiment and relevance, and aggregates insider trades from Maze Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.
1 min readVertex Pharmaceuticals (VRTX) and Maze Therapeutics (MAZE) saw stock increases after positive results from Vertex's kidney disease drug trial. Both companies are developing treatments for APOL1-mediated kidney disease (AMKD). Vertex tested its experimental treatment on patients with moderate proteinuria.
1 min readVertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.
2 min readMaze Therapeutics' Chief Medical Officer Harold Bernstein sold 9,705 shares at $26.22 each, per SEC filing. The sale, part of a pre-planned 10b5-1 trading plan, reduced his direct stake to zero. Maze Therapeutics' stock is down 50% from its 52-week high, and the company focuses on developing precision medicines for kidney and metabolic diseases.
2 min readMaze Therapeutics CEO Jason Coloma sold $594k worth of shares at $26.24 each, reducing his holding by 7.8%. This was the largest insider sale in the past year, occurring near the current stock price of $26.21. Insiders own 0.9% of the company's shares, valued at $13m. The article notes recent insider sales without corresponding buys, suggesting caution for investors.
1 min readCourtney Phillips (GC and Corp. Secretary) sold 3,993 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.10M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readDandekar Atul (CSBO) sold 6,434 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.81–$27.12, $0.17M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readColoma Jason V (Chief Executive Officer) sold 22,638 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.77–$27.12, $0.59M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readBernstein Harold (President, R&D & CMO) sold 10,295 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.27M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readColoma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.29 ($26.29–$26.31, $0.91M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min read
